医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

IASO Bio Establishes International CAR-T Diagnostic and Treatment Center in China to Serve MM Patients Worldwide

2023年11月21日 AM10:27
このエントリーをはてなブックマークに追加


 

NANJING, China

Nanjing IASO Biotechnology Co., Ltd. (IASO Bio) made its debut at the 6th China International Import Expo (CIIE) with FUCASO, the world’s first fully-human CAR-T, and entered into a strategic partnership with several international medical institutions, bringing hope for cure to multiple myeloma (MM) patients worldwide.

On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCASO) for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM). Meanwhile, the Equecabtagene Autoleucel Injection has received the Orphan Drug Designation, as well as the Regenerative Medicine Advanced Therapy and Fast Track Designations from the U.S. Food and Drug Administration, and has been approved for clinical trials in the U.S.

A single infusion of FUCASO can lead to lasting and deep remission with a favorable safety profile in patients with r/rMM who have failed multiple lines of therapy. Due to its unique design, FUCASO, as a fully-human CAR-T therapy, is able to persist in patients for a longer period of time, offering hope for overcoming the challenging problem of relapsed MM.

FUCASO has attracted patients from numerous countries around the world to seek treatment in Chinese hospitals in just 4 months since its approval for marketing in China. These hospitals have a world-leading level of full-process management in CAR-T therapy. In addition, the cost of treatment with FUCASO in China is significantly lower than that of similar products in Europe and America, which has benefited more patients worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231115683764/en/

CONTACT

Company: Nanjing IASO Biotechnology Co., Ltd

Contact Person: Zhang Yuanyuan

Email: Med-service@iasobio.com

Website: https://i-connection.iasobio.com/en

Telephone: 400 966 5315

同じカテゴリーの記事 

  • COP28召开前,全球医疗保健行业领导者加速推进行业脱碳
  •  COP28に先立ち世界のヘルスケアリーダーが産業全体の脱炭素化を推進
  • Global Healthcare Leaders Advance Sector Decarbonisation Ahead of COP28
  • Armis发布Armis Centrix™平台的第四季度更新
  • ケンビュー、来月6日の「モルガン・スタンレー世界消費者・小売会議」に参加へ